Drugs / MesoCancerVac
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02395679 | Jan → Dec 2015 | mesothelioma | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT01241682 | Oct 2009 → Oct 2011 | malignant pleural mesothelioma | Erasmus Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MesoCancerVac | “Three doses of properly pulsed autologous DCs (MesoCancerVac) are then re-injected every two weeks.” NCT01241682 ↗ |
| Modality | Cell therapy | “autologous tumor lysate-pulsed dendritic cell-based immunotherapy” PMID 26652184 ↗ May 2016 |
| Route | Intravenous | “10x10e6, 25x10e6 or 50x10e6 loaded dendritic cells i.d. and i.v. administration every two weeks” NCT02395679 ↗ |